Abstract:Over 100 modifications to RNA are known to occur in human cells, where they influence many aspects of RNA biology, including protein and nucleic acid interactions. Our survey of human RNA-modifying enzymes with selectively essential phenotypes in specific cancers, suggests that these cancer-essential enzymes fall into four mechanistic categories: group transfer enzymes; base editors; nucleases; and helicases. Our team has discovered nanomolar or picomolar inhibitors of cancer-essential enzymes within each of these four categories. DHX9, a novel cancer target, is a multifunctional DEAH-box RNA helicase which can unwind regions of double-stranded DNA and RNA helices but has a greater propensity for secondary structures such as DNA/RNA hybrids (R-loops), circular RNA and DNA/RNA G-quadruplexes. DHX9 interacts with and regulate a large variety of proteins, including key proteins in DNA damage repair pathways such as BRCA1, ATR, Ku86, and WRN. We previously demonstrated that DHX9 inhibition is selectively efficacious in microsatellite high (MSI-H)/defective mismatch repair (dMMR) tumor models, in vitro and in vivo. Further profiling of DHX9 inhibitors across a broad panel of cancer cell lines reveals that tumor cells with Loss-of-Function (LOF) mutations in the DNA damage repair genes BRCA1 and/or BRCA2 (as defined by somatic mutations including single-nucleotide variants and/or copy number loss), are also selectively responsive to DHX9 inhibitor treatment. Selective dependence on DHX9 was observed in both ovarian and breast cancer cell lines that exhibit BRCA1 and/or BRCA2 LOF. DHX9 inhibition leads to increased RNA/DNA secondary structures such as R-loops and G-quadruplexes, resulting in subsequent DNA damage and increased replication stress. Cell lines that exhibit BRCA1 and/or BRCA2 LOF appear unable to resolve this replication stress and showed S-G2 phase cell cycle arrest prior to onset of apoptosis. An orally bioavailable DHX9 inhibitor was dosed in vivo to assess DHX9 dependency within multiple human xenografts representing triple negative breast cancer and high-grade serous ovarian cancer with BRCA1 and/or BRCA2 LOF. In all models, DHX9 inhibition was well tolerated for a period of up to 28 days, with robust and significant tumor growth inhibition - including tumor regression - observed in multiple BRCA1 and/or BRCA2 LOF models; in contrast, minimal tumor growth inhibition was observed in BRCA1 and BRCA2 wild type models. These results portend DHX9 inhibition as a novel treatment modality for patients with BRCA1 and/or BRCA2 LOF across multiple tumor types, including breast and ovarian cancer. Citation Format: Robert A. Copeland, Jennifer Castro, Matthew H. Daniels, Deepali Gotur, Young-Tae Lee, Shihua Yao, David Brennan, Brian T. Johnston, Monique Laidlaw, Sunaina Pai, Jie Wu, Rishabh Bansal, Anugraha Raman, Shane M. Buker, Julie Liu, E. Allen Sickmier, Kevin Knockenhauer, Chuang Lu, Stephen J. Blakemore, Serena J. Silver, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Jason A. Sager. Small molecule inhibitors of RNA modifying enzymes as precision cancer therapeutics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr SY11-02.

Structural insights into IMP2 dimerization and RNA binding

IMP1 KH1 and KH2 domains create a structural platform with unique RNA recognition and re-modelling properties

Interactive Structural Analysis of KH3-4 Didomains of IGF2BPs with Preferred RNA Motif Having m6A Through Dynamics Simulation Studies

IGF2BP1 phosphorylation in the disordered linkers regulates ribonucleoprotein condensate formation and RNA metabolism

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Targeting RNA with small molecules, from RNA structures to precision medicines: IUPHAR review: 40

Structural mechanism of R2D2 and Loqs-PD synergistic modulation on DmDcr-2 oligomers

RNA Structure Probing Reveals the Structural Basis of Dicer Binding and Cleavage.

Molecular insights into the interaction between a disordered protein and a folded RNA

Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer

Structural Imprints in Vivo Decode RNA Regulatory Mechanisms

Exploring the Molecular Basis of RNA Recognition by the Dimeric RNA-binding Protein Via Molecular Simulation Methods

Molecular insight into the network of Drosophila cytoplasmic piRNA pathway proteins through a combination of systematic interaction screening and structural prediction

Targeting RNA structures with small molecules

The RNA binding protein IGF2BP2/IMP2 alters the cargo of cancer cell-derived extracellular vesicles supporting tumor-associated macrophages

Integrative solution structure of PTBP1-IRES complex reveals strong compaction and ordering with residual conformational flexibility

Interrogating RNA-Small Molecule Interactions with Structure Probing and Artificial Intelligence-Augmented Molecular Simulations

Abstract SY11-02: Small molecule inhibitors of RNA modifying enzymes as precision cancer therapeutics

Targeting insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) for the treatment of cancer

Structural Biology of RNA Silencing and Its Functional Implications